Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Russia says Sputnik Light is 70% effective against Delta variant

10/13/2021 | 11:38am EST

* Data shows Sputnik Light is effective against Delta - RDIF

* Will show it's a good booster for other vaccines - RDIF

* Sputnik light to become main Russian vaccine - RDIF

* Russia is battling soaring infections, vaccine hesitancy

MOSCOW, Oct 13 (Reuters) - Russia's Sputnik Light vaccine shows 70% effectiveness against the Delta variant of COVID-19 three months after injection and the one-shot product is likely to become the country's main vaccine, Russia's sovereign wealth fund said on Wednesday.

The findings are part of a Russian push to promote Sputnik Light as an effective standalone vaccine and as a booster that can be combined with non-Russian vaccines.

RDIF, the wealth fund which markets Sputnik Light abroad, cited data submitted by the developer, the Gamaleya Institute, to medical website medRxiv ahead of a peer review. The data was based on 28,000 participants who received a dose of Sputnik Light, and an unvaccinated control group of 5.6 million.

Russia is battling soaring infections and hesitancy about vaccines at home, while struggling to compete in some markets with Western vaccines developed by Pfizer, Moderna and AstraZeneca.

Countries around the world are deploying or considering administering third doses of Pfizer or Moderna as booster shots though there is no scientific consensus about how broadly they should be used.

When used as a booster for other vaccines, Sputnik Light, which comprises the first shot of Russia's two-shot flagship Sputnik V, will be over 83% effective against infection by the Delta variant and over 94% effective against hospitalisation, RDIF said in a statement.

Kirill Dmitriev, head of the RDIF, told Reuters he expected Sputnik Light to become Russia's main COVID-19 vaccine.

"Eventually, we believe that Sputnik Light could be the main vaccine one year from now when many people will just need to get revaccinated or will have had COVID and won't need Sputnik V," he said.


RDIF expects to produce enough Sputnik V and Sputnik Light for 700 million people this year, with around 50% of production already located abroad, Dmitriev said.

He said Russia wanted no more than 20-25% of the global market and had no ambition to take a monopoly position.

Argentina and some other counties were doing trials to combine Sputnik Light with AstraZeneca, Sinopharm and Moderna. Two countries were combining Pfizer and Sputnik Light, he said.

Alexander Gintsburg, director of the Gamaleya Institute, said Sputnik Light was easy and fast to produce.

Manufacturers have told Reuters that they have had difficulties producing the second Sputnik V dose.

RDIF had hoped to clinch regulatory approval for Sputnik V from the European Medicines Agency (EMA) and the World Health Organization (WHO) months ago, but it has taken longer than expected, depriving it of access to more markets.

Dmitriev said RDIF expected the WHO to approve Sputnik V for use by the end of the year. The WHO said on Wednesday approval for Sputnik V was on hold pending some missing data and legal procedures, which it hoped would be "sorted out quite soon".

Dmitriev said it was possible the EMA would grant approval by the end of this year as well. RDIF had got positive feedback from the EU on clinical trials and expected an EU inspection in the autumn, he said.

RDIF had applied for separate approval for the two components used in Sputnik V, and Sputnik Light would therefore be automatically approved at the same time, he added.

Dmitriev said Sputnik Light had already been registered in 15 countries and he expected it to be approved in 30 other countries in the next month.

The two-shot Sputnik V vaccine is registered in 70 countries. (Reporting by Polina Nikolskaya/Andrew Osborn; Additional reporting by Alexander Marrow in Moscow and by Jo Mason; Editing by Giles Elgood)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.62% 8327 Delayed Quote.13.00%
MODERNA, INC. -9.02% 321.22 Delayed Quote.237.35%
All news about ASTRAZENECA PLC
11:55aAstrazeneca To Scrap Plan For U.S. COVID Booster Study- Bloomberg News
11/30Oxford University Says Existing COVID-19 Vaccines Will Protect Against Omicron
11/30Officials offer vaccine reassurance; WHO advises against travel bans
11/30FTSE 100 marks worst month in over a year on Omicron hit
11/30AstraZeneca's Lynparza Secures FDA Priority Review for BRCA-Mutated HER2-Negative High-..
11/30ASTRAZENECA : Lynparza Gets FDA Priority Review -- Update
11/30Lynparza granted Priority Review in the US for BRCA-mutated HER2-negative high-risk ea..
11/30Genetron, AstraZeneca to Collaborate to Develop Solid Tumor Tests in China
11/30LONDON STOCK EXCHANGE : Doubts over vaccine efficiency send FTSE 100 down
11/30Presidential Taskforce On Covid-19 Endorses Pfizer-BioNTtech Vaccine for 12+ Year Olds
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 919 M - -
Net income 2021 3 423 M - -
Net Debt 2021 25 253 M - -
P/E ratio 2021 37,4x
Yield 2021 2,56%
Capitalization 170 B 171 B -
EV / Sales 2021 5,45x
EV / Sales 2022 4,46x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 110,04 $
Average target price 137,51 $
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.00%169 755
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741